| __timestamp | Alpine Immune Sciences, Inc. | Novavax, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 12199547 | 79435000 |
| Thursday, January 1, 2015 | 16054000 | 162644000 |
| Friday, January 1, 2016 | 23316000 | 237939000 |
| Sunday, January 1, 2017 | 10626000 | 168435000 |
| Monday, January 1, 2018 | 28970000 | 173797000 |
| Tuesday, January 1, 2019 | 35847000 | 113842000 |
| Wednesday, January 1, 2020 | 27185000 | 747027000 |
| Friday, January 1, 2021 | 58742000 | 2534508000 |
| Saturday, January 1, 2022 | 70243000 | 1235278000 |
| Sunday, January 1, 2023 | 80904000 | 737502000 |
Infusing magic into the data realm
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Alpine Immune Sciences, Inc. and Novavax, Inc. have shown contrasting approaches in their R&D investments. From 2014 to 2023, Novavax's R&D expenses surged by over 900%, peaking in 2021 with a staggering 2.5 billion dollars, driven by their COVID-19 vaccine efforts. In contrast, Alpine Immune Sciences, while more modest in scale, increased their R&D spending by approximately 560%, reaching 81 million dollars in 2023. This disparity highlights Novavax's aggressive push in the vaccine market, while Alpine focuses on niche immunotherapy solutions. As the biotech landscape evolves, these spending patterns offer a glimpse into each company's strategic priorities and potential future breakthroughs.
Research and Development: Comparing Key Metrics for Vertex Pharmaceuticals Incorporated and Novavax, Inc.
R&D Spending Showdown: Zoetis Inc. vs Novavax, Inc.
Biogen Inc. or Novavax, Inc.: Who Invests More in Innovation?
R&D Insights: How Incyte Corporation and Alpine Immune Sciences, Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Ascendis Pharma A/S and Novavax, Inc.
Comparing Innovation Spending: Ionis Pharmaceuticals, Inc. and Novavax, Inc.
R&D Insights: How Opthea Limited and Novavax, Inc. Allocate Funds
Comparing Innovation Spending: Alpine Immune Sciences, Inc. and Amicus Therapeutics, Inc.
Research and Development Expenses Breakdown: Alpine Immune Sciences, Inc. vs Viridian Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Alpine Immune Sciences, Inc. and Novavax, Inc.
Research and Development: Comparing Key Metrics for Viking Therapeutics, Inc. and Novavax, Inc.
Analyzing R&D Budgets: Veracyte, Inc. vs Novavax, Inc.